Emotion-driven momentum combined with southbound holdings increases: when will Cofoe Medical Technology (01187), having rebounded from the bottom, usher in a reversal?

date
11:51 19/11/2026
avatar
GMT Eight
Since November 11, the Hong Kong stock price of Cofoe Medical Technology (01187) has recorded a five-day winning streak. From November 11 to November 17, the stock's maximum interval gain reached 16.40%.
Since November 11, the Hong Kong stock price of Cofoe Medical Technology (01187) has staged a five-day winning streak. From November 11 to November 17, the stock's maximum intraday gain over the period reached 16.40%. Meanwhile, on-exchange trading in Cofoe Medical Technology's Hong Kong shares has also become noticeably more active than before. Over the three trading days from November 13 to 17, its daily trading volume all exceeded 500,000 shares, a marked increase from the preceding days. Catalyzed by the recent third-quarter report and the market's fermenting brain-computer interface concept, Cofoe Medical Technology's H-shareswhich trade at a significant discount to its A-shares and offer a higher valuation safety marginmay be embarking on a new rally. After bottoming out and rebounding, how far can this rally go? Looking at the trading action, from November 11 to 17, Cofoe Medical Technology's H-shares posted a cumulative gain of 10.41% over the period, with a maximum amplitude of 16.40%; meanwhile, the stock's turnover rate over the period surged from 0.36% to an average of more than 2% per day, marking a typical low-level, volume-expansion breakout. It was observed that on November 11, although Cofoe Medical Technology's stock price closed up only slightly by 0.37%, it formed a low-volume sideways pattern at the tail end of the prior decline, halting the downtrend since November 6 and stabilizing the closing price above the lower Bollinger Band for the day. In the subsequent four trading days from November 12 to 17, Cofoe Medical Technology's H-shares completed a three-stage move in just four sessions: from breakout initiation to high-level turnover, and then to a second accelerated push higher. In terms of the corresponding price-volume performance, its daily trading volumes over the four trading days were 196,000 shares, 719,800 shares, 666,300 shares and 588,700 shares, respectively, showing a "from period-record volume to new high on shrinking volume" pattern of rising on declining volume; cross-validated by the OBV indicator, it climbed continuously from 142,900 to 1,594,100, fully in sync with the stock's price movement over the period, with no top divergence between volume and price. This indicates to some extent that during this rally, the share price advance in Cofoe Medical Technology's H-shares was accompanied by easing selling pressure rather than sustained capital withdrawal. On the technical front, the MACD indicator shows that from November 11 to 17, DIF recovered continuously from -0.607 to -0.097; meanwhile, DEA recovered from -0.588 to -0.406, with the corresponding MACD histogram expanding from -0.038 to 0.617, indicating that bullish momentum for Cofoe Medical Technology was accelerating during the period; as for RSI, although Cofoe Medical Technology's RSI oscillated upward in the 50-53 range, it never touched the 70 overbought line, and on the November 13 pullback its RSI fell only to 43.2 (without breaking 50), then rose again to 52.9 on the 16th, with a complete structure of rising RSI lows, indicating that the medium-term momentum of Cofoe Medical Technology's share price remains healthy. By contrast, KDJ values continued to rise and diverge after the golden cross, with the J value exceeding 90 for two consecutive days, constituting a short-term overbought condition. On November 18, Cofoe Medical Technology's share price pulled back, with the corresponding MACD histogram narrowing slightly to 0.613; the first shortening of the red histogram indicates marginally weakening momentum, but the overall indicator still points to a bullish range; meanwhile, the KDJ-J value that had signaled short-term overbought fell to 75.5 that day and showed a high-level turn downward, further confirming a short-term correction signal for Cofoe Medical Technology's share price; even so, its K value remained above the D value, indicating that its KDJ golden-cross structure has not been broken. Combined with the capital direction indicated by the OBV indicator, on November 18, Cofoe Medical Technology's OBV remained at 1,460,400, a slight decline from the prior day but still far above the pre-breakout level of 142,900, with capital overall still showing net inflow. In summary, although Cofoe Medical Technology's H-shares during the November 18 pullback briefly broke below the 5-day moving average to an intraday low of HK$27.98, the closing price still held the 5-day line at HK$29. In other words, Cofoe Medical Technology's current performance still constitutes a technical pullback confirmation after a push higher; the bulls remaining intact means its share price may still have the potential for a second push higher. When will the sentiment-driven short-term rally shift into a reversal trend? Recently, the fifth batch of industry standard formulation and revision plans for 2026 was officially released, with nine industry standards under the jurisdiction of the Brain-Computer Interface Standardization Technical Committee (MIIT/TC4) approved for initiation. The policy tailwind has become one of the important factors influencing recent market sentiment. It is understood that although Cofoe Medical Technology's main business does not involve brain-computer interface operations, in recent years the company has, through strategic investments, established a presence in brain-computer interface-related fields: in 2024, the company invested in Niulingke Medical, involving an implantable brain-computer interface project; at the end of 2025, the company again invested in Lizhi Intelligence, positioning itself in non-invasive brain-computer interface Siasun Robot&Automation. However, the domestic brain-computer interface sector currently mainly exhibits characteristics of "high volatility and strong divergence," with concept generalization becoming the main problem in the sector at this stage. For Cofoe Medical Technology, this concept is essentially also an equity-investment option, and the company has explicitly stated that "its contribution to performance will be limited in the short term." In fact, the main factors driving this round of secondary-market sentiment may lie in the recent bottoming-out rebound trend in Cofoe Medical Technology's H-shares and the third-quarter report rally. It is understood that, taking the A-share market as an example, this year's third-quarter reports show that 5,572 companies reported total revenue of RMB56.66 trillion, up 5.66% year on year; corresponding net profit attributable to parent was RMB5.1 trillion, up 8.3% year on year, with 73.15% of listed companies achieving profitability. According to Cofoe Medical Technology's 26Q3 financial report disclosed after market close on October 29, the company's revenue for the first three quarters reached RMB3.191 billion, up 33.08% year on year; corresponding net profit attributable to parent was RMB305 million, up 17.30% year on year; meanwhile, the company's comprehensive gross margin for the period reached 56.24%, up 2.88 percentage points year on year. The gross margin for the third quarter alone reached 56.88%. Evidently, the solid fundamental performance shown in the third-quarter report actually provided important support for Cofoe Medical Technology's recent rally. During the bottoming-out rebound in Cofoe Medical Technology's H-share price, southbound capital went against its previous left-side trading strategy and chose right-side trading by adding positions in line with the trend. Taking a longer view, from November 5 to 17, southbound holdings in Cofoe Medical Technology rose from 21.64% to 23.73%. Based on total H-share capital of 27 million shares, southbound capital net added approximately 560,000 shares of Cofoe Medical Technology over the 11 trading days, holding a cumulative approximately 6.41 million shares. During this process, the pace of southbound accumulation was highly synchronized with the rebound in Cofoe Medical Technology's H-share price. In particular, on November 13, when Cofoe Medical Technology recorded period-record volume, southbound capital added 40,200 shares of the company on a single day; and on November 17, when Cofoe Medical Technology's share price hit a period high, the corresponding southbound holding ratio jumped to 23.73%. In fact, the southbound holding ratio mainly began to accelerate upward after Cofoe Medical Technology's cornerstone lock-up expired on November 5, so it cannot be ruled out that part of the reason for southbound capital increasing its holdings was to absorb shares during the cornerstone unlock window, but southbound capital likewise has an actively bullish logic for buying Cofoe Medical Technology. It is understood that 2027 will be the first commercialization year for Cofoe's CGM devices. Under the combined influence of the domestic CGM track's dual-edged sword of a import-substitution window and a price war, Cofoe's CGM devices are expected to leverage the company's reusable channel ecosystem and, relying on its own "shelf-style distribution efficiency," achieve a leapfrog catch-up with unit customer acquisition costs significantly lower than peers. Since the secondary market has not priced in any of the company's CGM expectations in its H-share performance, there may be a sizable expectation gap, which could become an important foundation for a future reversal in the company's share price.